Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02327013 · ClinicalTrials.gov registry record · Phase 2
Investigating the Effect of Vortioxetine in Adult ADHD Patients
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 15
- Study locations
NCT02327013 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by H. Lundbeck A/S. The registered enrollment target is 227 participants, above the 204-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (11% higher). The trial reports 15 study locations across 11 states.
The verdict
NCT02327013, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
Conditions Studied
Interventions
- OTHER Placebo tablet
- DRUG vortioxetine 10 mg tablet
- DRUG vortioxetine 20 mg tablet
Study Locations (15)
California
- US015 - Beverly Hills
- US002 - Garden Grove
- US004 - National City
Florida
- US013 - Bradenton
- US006 - Gainesville
New York
- US005 - New York
- US008 - New York
Georgia
- US010 - Alpharetta
Illinois
- US014 - Libertyville
Maryland
- US011 - Baltimore
Massachusetts
- US009 - Boston
Nevada
- US016 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02327013
The ClinicalTrials.gov registry entry for NCT02327013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 204-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (11% higher). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo tablet is the first listed.
NCT02327013 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02327013 about?
NCT02327013 is a clinical study titled "Investigating the Effect of Vortioxetine in Adult ADHD Patients". The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
What is the current status of trial NCT02327013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2014-12. Estimated completion is 2016-09.
What conditions does trial NCT02327013 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02327013?
The interventions under investigation include: Placebo tablet (OTHER), vortioxetine 10 mg tablet (DRUG), vortioxetine 20 mg tablet (DRUG).
Who is sponsoring clinical trial NCT02327013?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02327013 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.